Story · Medicine & Biotech

Pfizer leaps into ‘in vivo’ CAR-T with latest China deal

1 outlet · first reported by BioPharma Dive on

The potentially $2.6 billion collaboration puts Pfizer into a competitive race to treat autoimmune conditions by reprogramming cells inside the body. (BioPharma Dive)